Keywords: |
cancer survival; treatment outcome; disease-free survival; cisplatin; drug efficacy; antineoplastic agents; cancer radiotherapy; chemotherapy, adjuvant; radiotherapy, adjuvant; research design; cancer staging; follow up; neoplasm staging; tumor localization; carboplatin; multiple cycle treatment; neoplasm recurrence, local; etoposide; risk factors; randomized controlled trials as topic; editorial; time factors; risk assessment; radiation dosage; cardiovascular disease; testicular neoplasms; single drug dose; malignant neoplastic disease; cancer relapse; orchiectomy; seminoma; multicenter studies as topic; study design
|